Kamada Signs Deal To Supply Israel’s Health Ministry With COVID-19 Antibody Drug
Kamada developed a plasma-derived, investigational antibody treatment for COVID-19 currently under trial; interim results show promise.
October 19, 2020
Early Results For COVID-19 Trial With Antibody Drug Show 90% Improvement Rate
The trial involves 12 hospitalized but non-ventilated COVID-19 patients with pneumonia; 11 of them have been discharged, Kamada says.
September 09, 2020
Small Trial For COVID-19 Antibody Drug Gets Flying Start In Jerusalem
Hadassah hospital gave 3 people a new drug made from antibodies from people who had had coronavirus; they are all now home after an ‘astonishing’ recovery.
August 16, 2020
Israeli Biopharma Company Kamada To Roll Out Antibody Treatment For COVID-19
The Rehovot-based firm said it completed the manufacturing of the first batch of its plasma-derived IgG product for the novel coronavirus.
June 21, 2020
Israeli Biomed Firm BATM Launches Antibody Tests For COVID-19
BATM said it began filling initial shipping initial orders and will be 'ramping up production for larger quantities' for European customers.
May 06, 2020